New hope for rare stomach cancer: Triple-Drug attack before surgery
NCT ID NCT06992362
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs (RC48, SOX, and Sindilizumab) given before and after surgery for a rare and aggressive stomach cancer called hepatoid adenocarcinoma. The goal is to see if this approach can shrink tumors and improve outcomes. About 30 participants with HER2-expressing, locally advanced disease will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RC48 (Disitamab Vedotin), SOX (Oxaliplatin, Tegafur, Gimeracil, Oteracil Potassium), and Sindilizumab
- What this could lead to
- If successful, this could point toward a more effective treatment approach for a rare and aggressive stomach cancer, potentially improving surgical outcomes and long-term control.
- What could go wrong
- This is a small, early-phase (phase II) study with only 30 participants, so results may not apply broadly. The combination therapy may cause significant side effects, and it is not yet known if it will improve survival or cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOID ADENOCARCINOMA OF STOMACH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.